344 related articles for article (PubMed ID: 25874530)
21. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
22. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
[TBL] [Abstract][Full Text] [Related]
23. Association of the BDNF Val66Met polymorphism with BMI in chronic schizophrenic patients and healthy controls.
Fang H; Zhen YF; Liu XY; Xu G; Soares JC; Zhao J; Zhang XY
Int Clin Psychopharmacol; 2016 Nov; 31(6):353-7. PubMed ID: 27483421
[TBL] [Abstract][Full Text] [Related]
24. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.
Kemp DE; Zhao J; Cazorla P; Landbloom RP; Mackle M; Snow-Adami L; Szegedi A
J Clin Psychiatry; 2014 Mar; 75(3):238-45. PubMed ID: 24499969
[TBL] [Abstract][Full Text] [Related]
25. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
26. The BDNF Val66Met polymorphism is associated with lower BMI, lower postprandial glucose levels and elevated carbohydrate intake in children and adolescents.
Kalenda A; Landgraf K; Löffler D; Kovacs P; Kiess W; Körner A
Pediatr Obes; 2018 Mar; 13(3):159-167. PubMed ID: 28960774
[TBL] [Abstract][Full Text] [Related]
27. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Sikich L; Frazier JA; McClellan J; Findling RL; Vitiello B; Ritz L; Ambler D; Puglia M; Maloney AE; Michael E; De Jong S; Slifka K; Noyes N; Hlastala S; Pierson L; McNamara NK; Delporto-Bedoya D; Anderson R; Hamer RM; Lieberman JA
Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207
[TBL] [Abstract][Full Text] [Related]
28. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
Melkersson K; Berinder K; Hulting AL
Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
[TBL] [Abstract][Full Text] [Related]
29. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
Newcomer JW; Ratner RE; Eriksson JW; Emsley R; Meulien D; Miller F; Leonova-Edlund J; Leong RW; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):487-99. PubMed ID: 19358783
[TBL] [Abstract][Full Text] [Related]
30. Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine.
Chagnon YC; Bureau A; Gendron D; Bouchard RH; Mérette C; Roy MA; Maziade M
Am J Med Genet B Neuropsychiatr Genet; 2007 Dec; 144B(8):1063-9. PubMed ID: 17541984
[TBL] [Abstract][Full Text] [Related]
31. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
Bond DJ; Kauer-Sant'Anna M; Lam RW; Yatham LN
J Affect Disord; 2010 Jul; 124(1-2):108-17. PubMed ID: 19914720
[TBL] [Abstract][Full Text] [Related]
32. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Alméras N; Després JP; Villeneuve J; Demers MF; Roy MA; Cadrin C; Mottard JP; Bouchard RH
J Clin Psychiatry; 2004 Apr; 65(4):557-64. PubMed ID: 15119921
[TBL] [Abstract][Full Text] [Related]
33. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
Fraguas D; Merchán-Naranjo J; Laita P; Parellada M; Moreno D; Ruiz-Sancho A; Cifuentes A; Giráldez M; Arango C
J Clin Psychiatry; 2008 Jul; 69(7):1166-75. PubMed ID: 18588363
[TBL] [Abstract][Full Text] [Related]
34. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
Citrome L; Holt RI; Walker DJ; Hoffmann VP
Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
[TBL] [Abstract][Full Text] [Related]
35. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
Baptista T; Rangel N; Fernández V; Carrizo E; El Fakih Y; Uzcátegui E; Galeazzi T; Gutiérrez MA; Servigna M; Dávila A; Uzcátegui M; Serrano A; Connell L; Beaulieu S; de Baptista EA
Schizophr Res; 2007 Jul; 93(1-3):99-108. PubMed ID: 17490862
[TBL] [Abstract][Full Text] [Related]
36. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.
Hu S; Yao M; Peterson BS; Xu D; Hu J; Tang J; Fan B; Liao Z; Yuan T; Li Y; Yue W; Wei N; Zhou W; Huang M; Xu Y
Psychopharmacology (Berl); 2013 Nov; 230(1):3-13. PubMed ID: 23559220
[TBL] [Abstract][Full Text] [Related]
37. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
[TBL] [Abstract][Full Text] [Related]
38. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
[TBL] [Abstract][Full Text] [Related]
39. BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.
Miura I; Zhang JP; Nitta M; Lencz T; Kane JM; Malhotra AK; Yabe H; Correll CU
Schizophr Res; 2014 Feb; 152(2-3):365-72. PubMed ID: 24411528
[TBL] [Abstract][Full Text] [Related]
40. HOMA-IR increase after antidepressant treatment in depressed patients with the Met allele of the Val66Met BDNF genetic polymorphism.
Martin S; Colle R; El Asmar K; Rigal A; Vievard A; Feve B; Becquemont L; Verstuyft C; Corruble E
Psychol Med; 2019 Oct; 49(14):2364-2369. PubMed ID: 30526722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
